Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS0159 SAD/MAD and food effect in healthy subjects
NCT05624294Phase 1Completed
- Sponsor
- Cascade Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of linafexor in primary biliary cholangitis (PBC) (3 arms), sponsored by Cascade Pharmaceuticals. Primary endpoints: Incidence and severity of adverse events at Day 15, Dose PK Parameter(C-max) at Day 7 and 1 more. Started Dec 2022; status: completed.
02
Drugs
linafexor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT05624294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624294.